AbbVie announced that the Drug Evaluation Center (CDE) of the China Drug Administration has officially added AbbVie's selective Jak inhibitor upadacitinib to the list of certified breakthrough therapeutic agents. The proposed indications for upadacitinib being included in the breakthrough treatment program are: for adolescents and adults aged 12 and above with non-segmental vitiligo. Currently, the indications for upadacitinib to treat vitiligo are in phase 3 clinical research.
艾伯维：upadacitinib被CDE纳入突破性治疗品种名单
AbbVie: Upadacitinib included in CDE's list of breakthrough therapeutic varieties
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.